Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- ONL Therapeutics, Inc. has received a $1 million grant from the National Eye Institute (NEI) to continue advancement of ONL1204 — a novel, first-in- class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.
- Valeant Pharmaceuticals International, Inc.'s wholly-owned subsidiary Bausch + Lomb and Nicox S.A. announced the U.S. FDA has set a PDUFA date of August 24, 2017 for its decision on the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an intraocular pressure (IOP) lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma (OAG) or ocular hypertension (OHT).
- Additionally, Bausch + Lomb Canada announced the availability in Canada of BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%w/v — an innovative fast acting eye drop indicated for the treatment of itch associated with allergic conjunctivitis.
- NightstaRx Ltd. has commenced enrolling and dosing subjects in a Phase I/II clinical trial to treat patients with X-Linked Retinitis Pigmentosa (XLRP). This is reportedly the first clinical trial of its type in XLRP worldwide, and has been progressed from licensing to clinical trial in a period of just 18 months.
- Imprimis Pharmaceuticals, Inc. reported the publication of a paper in the peer-reviewed journal, Current Pharmaceutical Design, that provides a retrospective review of data and efficacy of Dropless Cataract Surgery®. The authors reportedly provide a retrospective review of data and efficacy of the Dropless® approach, examine the transzonular via cannula injection technique, and discuss the benefits of Dropless Therapy® to patients, physicians and their staff.
- Novaliq GmbH announced a strategic licensing agreement with AFT Pharmaceuticals (AFT) for the commercialization of Novaliq’s lead product NovaTears® in Australia and New Zealand. NovaTears is reportedly Novaliq’s first commercially available ophthalmic product for the treatment of evaporative dry eye diseases (DEDs).
- Glaukos Corporation announced the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted five-year extensions to three Category III CPT codes that describe insertion of aqueous drainage devices into the anterior chamber of the eye using Micro-Invasive Glaucoma Surgery (MIGS).
- NeuroVision Imaging LLC will participate in a new substudy with investigators at the University of California San Diego School of Medicine (UC San Diego) and the University of Southern California (USC) that will test a new investigational treatment for Alzheimer’s Disease through the use of its retinal imaging technology.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.